Fagron

From local player to global market leader and consolidator in the market of pharmaceutical compounding.

Fagron was founded in Rotterdam (the Netherlands) in 1990. Through a continuous focus on innovation, quality and solution-oriented thinking, Fagron obtained market leadership in pharmaceutical compounding in the Netherlands in just 7 years. Fagron’s successful strategy of optimizing and innovating customized pharmaceutical care in order to widen the therapeutic options of prescribers worldwide and improving patients’ quality of life. Its unique business model and the investments in innovation and product development resulted in the fact that Fagron is currently leading in pharmaceutical compounding and is active in 32 countries in Europe, the Americas, the Middle East, Africa, Asia and the Pacific. Fagron products and innovations are sold to over 200,000 customers in over 60 countries around the world.

Fagron is active in the following segments of pharmaceutical compounding:

Fagron Specialty Pharma Services: customized medication that is prepared in Fagron’s sterile, nuclear and non-sterile compounding facilities in Europe, North America, South America and South Africa.

Fagron Trademarks: innovative concepts, vehicles and formulations for pharmaceutical compounding that are developed by Fagron's R&D team, often in close cooperation with prescribers, pharmacies and universities.

Fagron Essentials: pharmaceutical raw materials, equipment and supplies that pharmacists need in order to be able to prepare medication in the pharmacy.

With over 2,000 employees Fagron generated turnover of € 473 million in 2015. In 2016, Fagron will further reinforce its worldwide market leadership based on a buy-and-build strategy and organic growth.

Fagron, Inc.

Fagron, Inc., is headquartered in St. Paul, Minnesota. The company has continued to grow through the years because of its innovation and ability to bring new products to the U.S. compounding market.

Since 1980, Fagron, Inc. has been a US Food and Drug Administration-registered pharmaceutical supplier, adhering strictly to current Good Manufacturing Practices (cGMP). Bulk Pharmaceutical Ingredients (BPI) are purchased from reputable, registered, and validated manufacturers. Incoming BPIs are initially quarantined, then sampled and tested for identity, strength, quality, and purity in our Quality Control Laboratories, using methods as set forth in the applicable monographs of USP, NF, British Pharmacopoeia (BP), or European Pharmacopoeia (EP). Repackaging is performed in our climate-monitored facility, then retested by Quality Control (QC) and reviewed by Quality Assurance (QA) before release to the market. Fagron, Inc. has been VAWD accredited since 2012 and is committed to preventing counterfeit, contaminated or diverted drugs from entering the United States drug supply. VAWD accreditation ensures that our distribution facility operates legitimately, is licensed in good standing, and is employing security and best practices for safely distributing prescription drugs. More about Fagron’s unique quality process can be found here.